← Oncology Approval Tracker

FDA DECISION ·

Calquence

acalabrutinib · AstraZeneca

Traditional approvalNew or expanded indicationMantle cell lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

With bendamustine and rituximab for adults with previously untreated mantle cell lymphoma who are ineligible for autologous hematopoietic stem cell transplantation.

LAMPGEN ANALYSIS

Why it matters

The ECHO study brought a BTK inhibitor into first-line chemoimmunotherapy for transplant-ineligible patients.

What research teams should watch

Document transplant eligibility and plan how a continuous oral drug fits around six cycles of chemotherapy.

PRIMARY RECORDS

Sources